Cognitive Enhancers in Depression: Research Review

In this podcast episode, we review the research on cognitive enhancement agents in depression.
00:00 Welcome
00:57 Quick Takes with Dr. Jim Phelps
01:38 Vortioxetine
02:11 Duloxetine
03:10 Amphetamines
03:48 Modafinil
05:30 Key Points
06:20 Credits & References
Key Points:
- Modafinil has been shown to improve cognition in non-depressed populations.
- Modafinil has a potential role in the treatment of depression either as an adjunct or as monotherapy.
- The FDA approved vortioxetine for cognitive dysfunction in depression in 2016.
- Some evidence points to duloxetine and other SSRIs being equivalent in efficacy regarding attention and executive function in depression.
- About amphetamines, it is still open about whether stimulants can be effective as monotherapy for depression.
- Remember: Lisdexamfetamine should not be combined with SSRIs or SNRIs due to an increased risk of serotonin syndrome.
Are you a mental health clinician and want to brush up on psychopharm prescribing? We have what you need! Find the rest of Psychopharmacology Institute podcasts here:
Itunes: itunes.apple.com/us/podcast/p...
Spotify: open.spotify.com/show/7lzv8HK...
Stitcher:
www.stitcher.com/s?fid=215561...
Google Podcasts: www.google.com/podcasts?feed=...
RSS:
psychopharmacology.libsyn.com/...
Website:
psychopharmacologyinstitute.c...
Email us at: [e-mail]